[
  {
    "ts": null,
    "headline": "Was Jim Cramer Right About Pfizer Inc. (PFE)?",
    "summary": "We recently published a list of Was Jim Cramer Right About These 12 Stocks? In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks that Jim Cramer discusses. Back in 2024, on May 17, a caller asked about Pfizer Inc. (NYSE:PFE), which had struggled post-COVID. Cramer […]",
    "url": "https://finnhub.io/api/news?id=c2211d1a11bec03d0967f91f0b733e9801a1d1962a7eeb0af7c0c063fd7d5d31",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747949001,
      "headline": "Was Jim Cramer Right About Pfizer Inc. (PFE)?",
      "id": 134658708,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently published a list of Was Jim Cramer Right About These 12 Stocks? In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks that Jim Cramer discusses. Back in 2024, on May 17, a caller asked about Pfizer Inc. (NYSE:PFE), which had struggled post-COVID. Cramer […]",
      "url": "https://finnhub.io/api/news?id=c2211d1a11bec03d0967f91f0b733e9801a1d1962a7eeb0af7c0c063fd7d5d31"
    }
  },
  {
    "ts": null,
    "headline": "Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer",
    "summary": "Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \"Astellas\") and Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from an open-label extension of the Phase 3 ARCHES (NCT02677896) study, reporting a five-year follow up of overall survival (OS) benefits and a 30% reduction in the risk of death in men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with XTANDI™ (enzalutamide), an androgen receptor pathway inhibitor (ARPI), plus androgen depri",
    "url": "https://finnhub.io/api/news?id=8a7efb8a0a259d9b043db2391c16cc0687d671685584e9c299fabed35d25c5ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747947600,
      "headline": "Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer",
      "id": 134658709,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \"Astellas\") and Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from an open-label extension of the Phase 3 ARCHES (NCT02677896) study, reporting a five-year follow up of overall survival (OS) benefits and a 30% reduction in the risk of death in men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with XTANDI™ (enzalutamide), an androgen receptor pathway inhibitor (ARPI), plus androgen depri",
      "url": "https://finnhub.io/api/news?id=8a7efb8a0a259d9b043db2391c16cc0687d671685584e9c299fabed35d25c5ee"
    }
  },
  {
    "ts": null,
    "headline": "Astellas And Pfizer's Xtandi(TM) (Enzalutamide) Shows Long-Term Overall Survival In Metastatic Hormone-Sensitive Prostate Cancer",
    "summary": "Astellas Pharma Inc: * ASTELLAS AND PFIZER'S XTANDI™ SHOWSLONG-TERMOVERALL SURVIVAL IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER * PFIZER INC - XTANDI PLUS ADT...",
    "url": "https://finnhub.io/api/news?id=c29a453a3f653b045e23f8a1e620eb1e59b4b4e27d89812ade0a8e5eab4a7e53",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747936755,
      "headline": "Astellas And Pfizer's Xtandi(TM) (Enzalutamide) Shows Long-Term Overall Survival In Metastatic Hormone-Sensitive Prostate Cancer",
      "id": 134653716,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Astellas Pharma Inc: * ASTELLAS AND PFIZER'S XTANDI™ SHOWSLONG-TERMOVERALL SURVIVAL IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER * PFIZER INC - XTANDI PLUS ADT...",
      "url": "https://finnhub.io/api/news?id=c29a453a3f653b045e23f8a1e620eb1e59b4b4e27d89812ade0a8e5eab4a7e53"
    }
  },
  {
    "ts": null,
    "headline": "COVID shots should target newer strains of JN.1 variant, US FDA advisers say",
    "summary": "U.S. Food and Drug Administrationadvisers unanimously recommended on Thursday that COVID-19vaccines for the 2025-26 period should target newer strains ofthe JN.1 variant. COVID...",
    "url": "https://finnhub.io/api/news?id=1fb7a923f52d7d7526d1844a4101e5c44dceb330184b12e0f085b8f4903516d6",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747932964,
      "headline": "COVID shots should target newer strains of JN.1 variant, US FDA advisers say",
      "id": 134653367,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "U.S. Food and Drug Administrationadvisers unanimously recommended on Thursday that COVID-19vaccines for the 2025-26 period should target newer strains ofthe JN.1 variant. COVID...",
      "url": "https://finnhub.io/api/news?id=1fb7a923f52d7d7526d1844a4101e5c44dceb330184b12e0f085b8f4903516d6"
    }
  },
  {
    "ts": null,
    "headline": "Tempus AI: I Believe In The Company's Cause",
    "summary": "Tempus AI: I Believe In The Company's Cause",
    "url": "https://finnhub.io/api/news?id=9ede8cfd338e771f53afcf66a10fccc3bc5f9afb951f18f3c80633d1495d0d08",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747928836,
      "headline": "Tempus AI: I Believe In The Company's Cause",
      "id": 134652978,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=9ede8cfd338e771f53afcf66a10fccc3bc5f9afb951f18f3c80633d1495d0d08"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Yields Vs. Treasury Yields",
    "summary": "While down a bit today, this week has seen a spike in long-term Treasury yields.",
    "url": "https://finnhub.io/api/news?id=e792e6fa8bbe3dc6ed6e95e0ca34feab8eb81f2713b7c25f4a37e996f7f0ca86",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747926900,
      "headline": "Dividend Yields Vs. Treasury Yields",
      "id": 134652844,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1407983911/image_1407983911.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "While down a bit today, this week has seen a spike in long-term Treasury yields.",
      "url": "https://finnhub.io/api/news?id=e792e6fa8bbe3dc6ed6e95e0ca34feab8eb81f2713b7c25f4a37e996f7f0ca86"
    }
  },
  {
    "ts": null,
    "headline": "COVID shots should target newer strains of JN.1 variant in 2025-26 campaign, US FDA advisers say",
    "summary": "May 22 - U.S. Food and Drug Administration advisers unanimouslyrecommended on Thursday that COVID-19 vaccines for the 2025-26period should target newer strains of the JN.1 variant. ...",
    "url": "https://finnhub.io/api/news?id=a44b72ecb105768850ca27850bdb44aa5572efeeafd26222d0cd52e18c0cc0d1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747926668,
      "headline": "COVID shots should target newer strains of JN.1 variant in 2025-26 campaign, US FDA advisers say",
      "id": 134652724,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "May 22 - U.S. Food and Drug Administration advisers unanimouslyrecommended on Thursday that COVID-19 vaccines for the 2025-26period should target newer strains of the JN.1 variant. ...",
      "url": "https://finnhub.io/api/news?id=a44b72ecb105768850ca27850bdb44aa5572efeeafd26222d0cd52e18c0cc0d1"
    }
  },
  {
    "ts": null,
    "headline": "MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot",
    "summary": "Moderna's voluntary withdrawal of the filing stems from the FDA's request for vaccine efficacy data from a phase III study on the experimental flu shot.",
    "url": "https://finnhub.io/api/news?id=c7ad18a86cebcebe4968f6d6ce52017eb78d12a42dd8a3c5bd548846eca4d846",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747925280,
      "headline": "MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot",
      "id": 134658710,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Moderna's voluntary withdrawal of the filing stems from the FDA's request for vaccine efficacy data from a phase III study on the experimental flu shot.",
      "url": "https://finnhub.io/api/news?id=c7ad18a86cebcebe4968f6d6ce52017eb78d12a42dd8a3c5bd548846eca4d846"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Undervalued In Light Of Key Risks",
    "summary": "Merck: Undervalued In Light Of Key Risks",
    "url": "https://finnhub.io/api/news?id=2cf83a06c667d933b5230efc127d32ca765138c4065e6106fe71e2e81afcac58",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747917000,
      "headline": "Merck: Undervalued In Light Of Key Risks",
      "id": 134651888,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=2cf83a06c667d933b5230efc127d32ca765138c4065e6106fe71e2e81afcac58"
    }
  },
  {
    "ts": null,
    "headline": "5 Low Price-to-Sales Stocks That Can Deliver Big Returns in 2025",
    "summary": "The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like GDOT, JAKK, PCB, ROCK and PFE hold promise.",
    "url": "https://finnhub.io/api/news?id=7f4b584ae51a466ef79a000929f2cb3048738185ce931e67160a0cf79cc83789",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747914120,
      "headline": "5 Low Price-to-Sales Stocks That Can Deliver Big Returns in 2025",
      "id": 134649316,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like GDOT, JAKK, PCB, ROCK and PFE hold promise.",
      "url": "https://finnhub.io/api/news?id=7f4b584ae51a466ef79a000929f2cb3048738185ce931e67160a0cf79cc83789"
    }
  },
  {
    "ts": null,
    "headline": "US FDA advisers to weigh composition of COVID vaccines for 2025-2026",
    "summary": "The U.S. Food and DrugAdministration's advisory panel is set to vote on Thursday torecommend whether COVID-19 vaccines for the 2025-2026immunization campaign should target strains of the...",
    "url": "https://finnhub.io/api/news?id=0d3d631c653bbc001e43045ec764c695eae496932ac82daed76b5fb3082c9bc0",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747909389,
      "headline": "US FDA advisers to weigh composition of COVID vaccines for 2025-2026",
      "id": 134650776,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "The U.S. Food and DrugAdministration's advisory panel is set to vote on Thursday torecommend whether COVID-19 vaccines for the 2025-2026immunization campaign should target strains of the...",
      "url": "https://finnhub.io/api/news?id=0d3d631c653bbc001e43045ec764c695eae496932ac82daed76b5fb3082c9bc0"
    }
  },
  {
    "ts": null,
    "headline": "Prices for new US drugs doubled in 4 years as focus on rare disease grows",
    "summary": "U.S. prices for newly-launchedpharmaceuticals more than doubled last year compared to 2021, ascompanies leveraged scientific advances to develop moretherapies for rare diseases, which typically...",
    "url": "https://finnhub.io/api/news?id=67679a155e652f136b47839a6d7e5728ea4b61d14faa22bbcaea76010aa3c4ed",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747893749,
      "headline": "Prices for new US drugs doubled in 4 years as focus on rare disease grows",
      "id": 134646981,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "U.S. prices for newly-launchedpharmaceuticals more than doubled last year compared to 2021, ascompanies leveraged scientific advances to develop moretherapies for rare diseases, which typically...",
      "url": "https://finnhub.io/api/news?id=67679a155e652f136b47839a6d7e5728ea4b61d14faa22bbcaea76010aa3c4ed"
    }
  },
  {
    "ts": null,
    "headline": "Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT)",
    "summary": "Let’s dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded pharmaceuticals earnings season.",
    "url": "https://finnhub.io/api/news?id=280b9ff331a98cc0484ab060858e98a391f48da5585fe3ae814cbcd058b6b35a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747884660,
      "headline": "Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT)",
      "id": 134658712,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Let’s dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded pharmaceuticals earnings season.",
      "url": "https://finnhub.io/api/news?id=280b9ff331a98cc0484ab060858e98a391f48da5585fe3ae814cbcd058b6b35a"
    }
  }
]